The Claim
The recombinant exendin-4 human serum albumin fusion protein E2HSA has a terminal elimination half-life of approximately 54 hours in healthy rhesus monkeys, which indicates a significantly prolonged circulation time compared to native exendin-4 and may support less frequent dosing in therapeutic applications.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A new diabetes drug version lasts much longer in the body—about two and a half days—compared to the original, so you might only need to take it once a week instead of every day.
See the scientific wording
The recombinant exendin-4 human serum albumin fusion protein E2HSA has a terminal elimination half-life of approximately 54 hours in healthy rhesus monkeys, indicating a significantly prolonged circulation time compared to native exendin-4, which may support less frequent dosing in therapeutic applications.
What the research says
1 studyThe study tested the same drug mentioned in the claim and found it lasts about 54 hours in monkeys, just like the claim says, so it supports it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.